Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 5/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21990516 | 0.87 | KDR (0.33) | PIK3CDPIK3CAPIK3CBPIK3CGKDR | |
| SCHEMBL21990475 | 0.82 | CSF1R (0.33) | PIK3CDPIK3CAPIK3CBPIK3CGKDR | |
| SCHEMBL21990566 | 0.78 | GRM2 (0.35) | PIK3CDPIK3CAPIK3CBPIK3CGKDR | |
| SCHEMBL21990688 | 0.76 | DPP4 (0.40) | PIK3CDPIK3CAPIK3CBKDRDPP4 | |
| SCHEMBL21990466 | 0.75 | PARP1 (0.31) | KDRDPP4 | |
| SCHEMBL21990467 | 0.74 | MAPK1 (0.34) | PIK3CDPIK3CAPIK3CBPIK3CGKDR | |
| SCHEMBL22011642 | 0.74 | MAPKAPK2 (0.39) | — | |
| SCHEMBL30543379 | 0.70 | CLK4 (0.37) | PIK3CDPIK3CAPIK3CBKDRDPP4 | |
| SCHEMBL1579192 | 0.70 | CLK4 (0.37) | PIK3CDPIK3CAPIK3CBKDRDPP4 | |
| SCHEMBL21990677 | 0.69 | GRM2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880676-B1 | 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PFIZER (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11142525-B2 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-20200172539-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172539-A1 | Azalactam Compounds as HPK1 Inhibitors | CDKN1A, HIPK1, CMPK1 | TAAR1 3206/4885PIK3CD 892/4885PIK3CA 398/4885 |
| US-11142525-B2 | Azalactam compounds as HPK1 inhibitors | CDKN1A, HIPK1, CMPK1 | TAAR1 3206/4885PIK3CD 892/4885PIK3CA 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.